Skip to main content
OpenTrials
Completed

NCT Number: NCT02198859

Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer

Laboratory testing has suggested that lithium may decrease the incidence of certain types of cancer, including prostate cancer. Additional research has suggested that lithium decreases prostate cancer tumor size over time. This study will investigate the effect of lithium on men with prostate cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

About this study

As lithium has been shown in an in vitro model to suppress cellular proliferation, and suppress tumor growth in an in vivo xenograft model, we propose to determine its effect on prostate cancer cells in human patients undergoing radical prostatectomy. In this pilot study we plan to assess the toxicity of lithium administration in patients prior to radical prostatectomy. This will include any clinical toxicity as well as any increase in intra-, peri- or postoperative complications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to understand and the willingness to sign a written informed consent form.
  • Subjects with histologically confirmed local adenocarcinoma of the prostate who have elected to proceed with radical prostatectomy as primary curative therapy.
  • Subjects having no prior administration of lithium or lithium containing medications within 90 days of study enrollment.
  • Subjects >/= 18 years of age.
  • ECOG (Eastern Cooperative Oncology Group) performance status of </= 1.
  • Adequate renal function defined as GFR (Glomerular Filtration Rate) >/= 50 mL/min.
  • Use of adequate contraception
  • ECG (Electrocardiogram) within normal limits.
  • Subjects must agree not to take any new vitamin supplements or herbal remedy during the study period.
  • Subjects must be able to safety take lithium carbonate for at least 4 weeks before scheduled prostatectomy.

Exclusion criteria

  • Subjects who have received any investigational medication within 30 days of first lithium dose.
  • Subjects currently receiving, or who have had previous hormonal, chemotherapy or radiotherapy for prostate cancer.
  • Subjects with known brain metastases.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lithium carbonate.
  • Uncontrolled intercurrent illness such as ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements.

Treatment and study plan

Lithium Carbonate

Drug

Primary outcomes

  1. Observe any change to Performance Status and Adverse Events related to Lithium

    Time frame: Weekly for 4 weeks prior to radical prostatectomy and continuing for 1 - 2 weeks after surgery

    To determine the safety and tolerability of lithium in subjects with clinically localized prostate cancer.

Secondary outcomes

  1. Serum lithium levels

    Time frame: Weekly for up to 4 weeks prior to radical prostatectomy

    To document observed levels of lithium in the serum

Other outcomes

  1. Tumor response by lithium concentration

    Time frame: Sample collected during surgery and up to 4 weeks after baseline

    To evaluate tumor response by lithium concentration in the surgically removed prostate and serum PSA levels.

Sponsors and collaborators

Lead sponsor

University of Kansas Medical Center

Other

Registry information

Official study title

Phase 1 Study of Evaluation of Lithium and it's Effect on Clinically Localized Prostate Cancer.

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Jul 24, 2014
Registry last updated
Jan 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.